Actively Recruiting
Phase 2 Trial of MR-Guided Radiation Therapy with Risk-Based Dose Adjustment for Anal Squamous Cell Carcinoma
Led by University Health Network, Toronto · Updated on 2026-06-10
80
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a phase II, open-label trial of MR-guided radiation therapy RT with risk-adapted dose selection in patients with anal squamous cell carcinoma SCC. The study divides patients into four risk groupslow, standard, intermediate, and highto tailor radiation doses. It also analyzes human papillomavirus HPV DNA to identify new biomarkers that may predict response and toxicity to chemoradiotherapy CRT. Patients receive radiation therapy delivered using an MR-Linac for precise image-guided radiation therapy. The radiation dose varies by risk group 20 fractions over 4 weeks for low risk, 25 fractions over 5 weeks for standard risk, 30 fractions over 6 weeks for intermediate risk, and 35 fractions over 7 weeks for high risk. Treatment plans are based on clinical and biological markers to optimize therapy. During the study, participants will be followed for up to 5 years with regular clinic visits and questionnaires to assess outcomes and quality of life. They may also choose to provide blood and tissue samples for research. The main outcome measured is the change in locoregional failure at 2 years, with additional evaluations including distant metastasis, colostomy rate, survival, toxicity, and patient-reported outcomes. This long-term monitoring supports understanding the treatments effects and safety.
CONDITIONS
Brief Title
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Research Team
A
Ali Hosni
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
